We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Immunovant, Inc. (IMVT - Free Report) . Shares have lost about 0.6% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Immunovant due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant reported second-quarter fiscal 2026 net loss of 73 cents per share, wider than the Zacks Consensus Estimate of a loss of 72 cents. In the year-ago quarter, the company reported a loss of 74 cents per share.
Excluding stock-based compensation expense, IMVT reported a net loss of 65 cents per share.
Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues.
IMVT’s Q2 Results in Detail
Research and development expenses totaled $114.2 million, up 17.4% from the year-ago quarter’s figure. The increase was mainly due to activities related to the clinical studies of IMVT-1402, including contract manufacturing costs and increased personnel-related expenses.
General and administrative expenses amounted to $17.5 million, down 5.1% year over year, mostly due to the streamlining of administrative processes to drive effective cost management strategies.
As of Sept. 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $521.9 million compared with $598.9 million as of June 30, 2025. IMVT expects its cash runway to fund clinical activities through 2027.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Immunovant has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Immunovant has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Immunovant belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM - Free Report) , has gained 0.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.
Insmed reported revenues of $142.34 million in the last reported quarter, representing a year-over-year change of +52.3%. EPS of -$1.75 for the same period compares with -$1.27 a year ago.
For the current quarter, Insmed is expected to post a loss of $1.39 per share, indicating a change of -5.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.4% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Insmed. Also, the stock has a VGM Score of F.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Immunovant, Inc. (IMVT - Free Report) . Shares have lost about 0.6% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Immunovant due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant reported second-quarter fiscal 2026 net loss of 73 cents per share, wider than the Zacks Consensus Estimate of a loss of 72 cents. In the year-ago quarter, the company reported a loss of 74 cents per share.
Excluding stock-based compensation expense, IMVT reported a net loss of 65 cents per share.
Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues.
IMVT’s Q2 Results in Detail
Research and development expenses totaled $114.2 million, up 17.4% from the year-ago quarter’s figure. The increase was mainly due to activities related to the clinical studies of IMVT-1402, including contract manufacturing costs and increased personnel-related expenses.
General and administrative expenses amounted to $17.5 million, down 5.1% year over year, mostly due to the streamlining of administrative processes to drive effective cost management strategies.
As of Sept. 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $521.9 million compared with $598.9 million as of June 30, 2025. IMVT expects its cash runway to fund clinical activities through 2027.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
VGM Scores
Currently, Immunovant has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Immunovant has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Immunovant belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM - Free Report) , has gained 0.3% over the past month. More than a month has passed since the company reported results for the quarter ended September 2025.
Insmed reported revenues of $142.34 million in the last reported quarter, representing a year-over-year change of +52.3%. EPS of -$1.75 for the same period compares with -$1.27 a year ago.
For the current quarter, Insmed is expected to post a loss of $1.39 per share, indicating a change of -5.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.4% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Insmed. Also, the stock has a VGM Score of F.